Luc Beuzit1, Julien Edeline2, Vanessa Brun3, Maxime Ronot4, Anne Guillygomarc'h5, Karim Boudjema6, Yves Gandon3, Etienne Garin7, Yan Rolland8. 1. Department of Radiology, Rennes University Hospital, 2 Rue Henri Le Guilloux, 35000 Rennes, France. Electronic address: lucbeuzit@yahoo.fr. 2. Department of Medical Oncology, Comprehensive Cancer Center, Institute Eugène Marquis, Rennes, France. 3. Department of Radiology, Rennes University Hospital, 2 Rue Henri Le Guilloux, 35000 Rennes, France. 4. Department of Radiology, Beaujon University Hospital, Assistance Publique Hopitaux de Paris, Clichy, France. 5. Department of Hepatology, Rennes University Hospital, Rennes, France. 6. Department of Digestive Surgery, Rennes University Hospital, Rennes, France. 7. Department of Nuclear Medicine, Comprehensive Cancer Center, Institute Eugène Marquis, Rennes, France. 8. Department of Radiology, Comprehensive Cancer Center, Institute Eugène Marquis, Rennes, France.
Abstract
OBJECTIVE: To compare Choi criteria with Response Evaluation Criteria in Solid Tumors (RECIST) for the prediction of overall survival (OS) in patients treated with glass-microspheres, Yttrium-90 selective internal radiation therapy (SIRT) for intrahepatic cholangiocarcinoma (ICC). METHODS: Between 2010 and 2014, 45 adult patients with locally advanced ICC treated with SIRT were retrospectively analyzed. Computed tomography scans performed before and after treatment were analyzed using both RECIST 1.1 and Choi criteria. Response was correlated with survival. RESULTS: Patients who achieved an objective response according to Choi had a longer OS than non-responders (median OS 19.9 months [95% CI, 1.1-38.7 months] vs. 7.5 months if stable disease [uncountable CI] and 3 months if progressive disease [95% CI, 0-6.2 months], log-rank test: p=0.003) whereas there was no significant survival difference according to the RECIST response (p=0.339). Among the 39 RECIST non-responding patients, those identified as responders by Choi (n=31) had significantly better OS than Choi non-responders (median OS 19.9 months (95% CI, 5.1-34.7 months) and 5.4 months (95% CI, 0-11.6 months), p=0.005). CONCLUSIONS: Choi criteria appear more appropriate than RECIST to identify responders with long survival among patients who received SIRT for ICC.
OBJECTIVE: To compare Choi criteria with Response Evaluation Criteria in Solid Tumors (RECIST) for the prediction of overall survival (OS) in patients treated with glass-microspheres, Yttrium-90 selective internal radiation therapy (SIRT) for intrahepatic cholangiocarcinoma (ICC). METHODS: Between 2010 and 2014, 45 adult patients with locally advanced ICC treated with SIRT were retrospectively analyzed. Computed tomography scans performed before and after treatment were analyzed using both RECIST 1.1 and Choi criteria. Response was correlated with survival. RESULTS:Patients who achieved an objective response according to Choi had a longer OS than non-responders (median OS 19.9 months [95% CI, 1.1-38.7 months] vs. 7.5 months if stable disease [uncountable CI] and 3 months if progressive disease [95% CI, 0-6.2 months], log-rank test: p=0.003) whereas there was no significant survival difference according to the RECIST response (p=0.339). Among the 39 RECIST non-responding patients, those identified as responders by Choi (n=31) had significantly better OS than Choi non-responders (median OS 19.9 months (95% CI, 5.1-34.7 months) and 5.4 months (95% CI, 0-11.6 months), p=0.005). CONCLUSIONS: Choi criteria appear more appropriate than RECIST to identify responders with long survival among patients who received SIRT for ICC.
Authors: Héloïse Bourien; Xavier Palard; Yan Rolland; Fanny Le Du; Luc Beuzit; Thomas Uguen; Samuel Le Sourd; Marc Pracht; Vincent Manceau; Astrid Lièvre; Karim Boudjema; Etienne Garin; Julien Edeline Journal: Eur J Nucl Med Mol Imaging Date: 2018-10-29 Impact factor: 9.236
Authors: Mª Pilar Solis-Hernandez; Ana Fernandez Del Valle; Alberto Carmona-Bayonas; Rocio Garcia-Carbonero; Ana Custodio; Marta Benavent; Teresa Alonso Gordoa; Bárbara Nuñez-Valdovino; Manuel Sanchez Canovas; Ignacio Matos; Vicente Alonso; Carlos Lopez; Antonio Viudez; Marta Izquierdo; David Calvo-Temprano; Enrique Grande; Jaume Capdevila; Paula Jimenez-Fonseca Journal: Br J Cancer Date: 2019-09-03 Impact factor: 7.640
Authors: M Weber; M Lam; C Chiesa; M Konijnenberg; M Cremonesi; P Flamen; S Gnesin; L Bodei; T Kracmerova; M Luster; E Garin; K Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-11 Impact factor: 9.236